Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Leases (2019 - 2025)

Historic Current Leases for Cartesian Therapeutics (RNAC) over the last 7 years, with Q3 2025 value amounting to $3.9 million.

  • Cartesian Therapeutics' Current Leases rose 3992.78% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 3992.78%. This contributed to the annual value of $2.9 million for FY2024, which is 3162.51% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' Current Leases stood at $3.9 million, which was up 3992.78% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Current Leases registered a high of $3.9 million during Q3 2025, and its lowest value of $942000.0 during Q1 2021.
  • Its 5-year average for Current Leases is $2.0 million, with a median of $1.7 million in 2023.
  • Per our database at Business Quant, Cartesian Therapeutics' Current Leases tumbled by 4071.6% in 2021 and then surged by 6617.32% in 2025.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Current Leases stood at $1.0 million in 2021, then skyrocketed by 53.29% to $1.6 million in 2022, then soared by 34.7% to $2.2 million in 2023, then surged by 31.63% to $2.9 million in 2024, then skyrocketed by 35.95% to $3.9 million in 2025.
  • Its Current Leases stands at $3.9 million for Q3 2025, versus $3.8 million for Q2 2025 and $3.7 million for Q1 2025.